{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:12:14Z","timestamp":1787069534457,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2013,5,3]],"date-time":"2013-05-03T00:00:00Z","timestamp":1367539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>Untreated, hypoparathyroidism (hypoPT) is a state of hypocalcemia with inappropriately low plasma parathyroid hormone (PTH) levels and hyperphosphatemia. PTH administration normalizes plasma calcium and phosphate levels and reduces the doses of calcium and active vitamin D analogues needed. To develop an evidence-based clinical algorithm to monitor hypoPT patients treated with recombinant human PTH (rhPTH[1-84]) injected subcutaneously in the thigh, we performed a 24-hour monitoring study of pharmacokinetic and pharmacodynamic effects in a group of 38 patients who had completed a 6-month randomized study on effects of treatment with a fixed rhPTH(1-84) dose of 100\u2009\u00b5g\/d or similar placebo as an add-on to conventional treatment. PTH levels rose immediately, reaching a median peak level of 26.5 (interquartile range [IQR], 20.1\u201342.5) pmol\/L 15 minutes following injection. Thereafter, levels gradually decreased until reaching predosing levels after 16 hours, with a plasma half-life of 2.2 (1.7\u20132.5) hours. rhPTH(1-84) changed the diurnal rhythms of ionized calcium levels and 1,25-dihydroxyvitamin D (1,25[OH]2D) levels, with rising levels following injection. Ionized calcium peaked after 7.0 (5.0\u201310.0) hours. Asymptomatic hypercalcemia was present in 71% of the rhPTH(1-84)-treated patients. Compared with placebo, 24-hour urinary calcium, phosphate, and magnesium did not change, although the diurnal variation in renal excretion rates changed significantly in response to treatment. In conclusion, as a safety precaution, we recommend occasionally measuring calcium levels at approximately 7 hours after administration in order to reveal episodes of hypercalcemia. A 100-\u00b5g daily dose of rhPTH(1-84) appears to be too high in some patients, suggesting a need for a device allowing for individual dose adjustments. \u00a9 2013 American Society for Bone and Mineral Research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.1964","type":"journal-article","created":{"date-parts":[[2013,5,3]],"date-time":"2013-05-03T08:30:18Z","timestamp":1367569818000},"page":"2232-2243","source":"Crossref","is-referenced-by-count":75,"title":["PTH(1-84) replacement therapy in hypoparathyroidism: A randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment"],"prefix":"10.1093","volume":"28","author":[{"given":"Tanja","family":"Sikjaer","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Internal MedicineMEA, Aarhus University HospitalAarhusDenmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kristine","family":"Amstrup","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal MedicineMEA, Aarhus University HospitalAarhusDenmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rolighed","sequence":"additional","affiliation":[{"name":"Department of Surgery PAarhus University HospitalAarhusDenmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soren Geill","family":"Kjaer","sequence":"additional","affiliation":[{"name":"Department of Internal MedicineSilkeborg Regional HospitalSilkeborgDenmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Mosekilde","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal MedicineMEA, Aarhus University HospitalAarhusDenmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rejnmark","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal MedicineMEA, Aarhus University HospitalAarhusDenmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,5,3]]},"reference":[{"key":"2024020318351944200_jbmr1964-bib-0001","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","article-title":"Clinical practice. Hypoparathyroidism","volume":"359","author":"Shoback","year":"2008","journal-title":"N Engl J Med."},{"key":"2024020318351944200_jbmr1964-bib-0002","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA."},{"key":"2024020318351944200_jbmr1964-bib-0003","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318351944200_jbmr1964-bib-0004","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318351944200_jbmr1964-bib-0005","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318351944200_jbmr1964-bib-0006","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318351944200_jbmr1964-bib-0007","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","volume":"21","author":"Rubin","year":"2010","journal-title":"Osteoporos Int."},{"key":"2024020318351944200_jbmr1964-bib-0008","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318351944200_jbmr1964-bib-0009","first-page":"869","article-title":"Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers","volume":"62","author":"Chu","year":"2007","journal-title":"Pharmazie."},{"key":"2024020318351944200_jbmr1964-bib-0010","article-title":"Relationships between pharmacokinetic profile of human PTH(1-84) and serum calcium response in postmenopausal women following four different methods of administration","volume":"26","author":"Fox","year":"2011","journal-title":"J Bone Miner Res [Internet]."},{"key":"2024020318351944200_jbmr1964-bib-0011","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11596-009-0408-6","article-title":"Safety, tolerability and pharmacokinetic study of recombinant human parathyroid hormone [rhPTH (1-84)] in Chinese healthy volunteers","volume":"29","author":"Li","year":"2009","journal-title":"J Huazhong Univ Sci Technolog Med Sci."},{"key":"2024020318351944200_jbmr1964-bib-0012","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0009-9236(97)90169-7","article-title":"Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers","volume":"61","author":"Schwietert","year":"1997","journal-title":"Clin Pharmacol Ther."},{"key":"2024020318351944200_jbmr1964-bib-0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2265.1994.tb03934.x","article-title":"Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen","volume":"40","author":"Laursen","year":"1994","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2024020318351944200_jbmr1964-bib-0014","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2337\/diacare.7.2.188","article-title":"Insulin pharmacokinetics","volume":"7","author":"Binder","year":"1984","journal-title":"Diabetes Care."},{"key":"2024020318351944200_jbmr1964-bib-0015","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1373\/clinchem.2005.052936","article-title":"Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3","volume":"51","author":"Maunsell","year":"2005","journal-title":"Clin Chem."},{"key":"2024020318351944200_jbmr1964-bib-0016","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2009.10.010","article-title":"High-throughput liquid-liquid extraction and LCMSMS assay for determination of circulating 25(OH) vitamin D3 and D2 in the routine clinical laboratory","volume":"411","author":"Hojskov","year":"2010","journal-title":"Clinica Chimica Acta."},{"key":"2024020318351944200_jbmr1964-bib-0017","first-page":"1","author":"FDA, ICH 2011 Guidance for Industry","year":"2011"},{"key":"2024020318351944200_jbmr1964-bib-0018","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318351944200_jbmr1964-bib-0019","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P","article-title":"Lymphatic transport of proteins after subcutaneous administration","volume":"89","author":"Porter","year":"2000","journal-title":"J Pharm Sci."},{"key":"2024020318351944200_jbmr1964-bib-0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","article-title":"Subcutaneous drug delivery and the role of the lymphatics","volume":"2","author":"McLennan","year":"2005","journal-title":"Drug Discov Today Technol."},{"key":"2024020318351944200_jbmr1964-bib-0021","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0169-409X(01)00153-3","article-title":"Lymphatic transport of proteins after s.c. injection: implications of animal model selection","volume":"50","author":"Porter","year":"2001","journal-title":"Adv Drug Deliv Rev."},{"key":"2024020318351944200_jbmr1964-bib-0022","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/9780470623992.ch28","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"Bikle","year":"2008"},{"key":"2024020318351944200_jbmr1964-bib-0023","doi-asserted-by":"crossref","first-page":"F1032","DOI":"10.1152\/ajprenal.00306.2002","article-title":"PTH increases renal 25(OH)D3-1alpha -hydroxylase (CYP1alpha) mRNA but not renal 125(OH)2D3 production in adult rats","volume":"284","author":"Armbrecht","year":"2003","journal-title":"Am J Physiol Renal Physiol."},{"key":"2024020318351944200_jbmr1964-bib-0024","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00230148","article-title":"The relationship of calcium and parathyroid hormone in their effect on heart cells","volume":"77","author":"Bogin","year":"1987","journal-title":"Mol Cell Biochem."},{"key":"2024020318351944200_jbmr1964-bib-0025","first-page":"H1945","article-title":"Parathyroid hormone: an endogenous modulator of cardiac calcium channels","volume":"261","author":"Rampe","year":"1991","journal-title":"Am J Physiol."},{"key":"2024020318351944200_jbmr1964-bib-0026","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0014-5793(91)80507-Y","article-title":"The effects of parathyroid hormone on L-type voltage-dependent calcium channel currents in vascular smooth muscle cells and ventricular myocytes are mediated by a cyclic AMP dependent mechanism","volume":"282","author":"Wang","year":"1991","journal-title":"FEBS Lett."},{"key":"2024020318351944200_jbmr1964-bib-0027","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI110137","article-title":"Effect of parathyroid hormone on rat heart cells","volume":"67","author":"Bogin","year":"1981","journal-title":"J Clin Invest."},{"key":"2024020318351944200_jbmr1964-bib-0028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1124\/jpet.107.123901","article-title":"Systemic activation of the calcium sensing receptor produces acute effects on vascular tone and circulatory function in uremic and normal rats: focus on central versus peripheral control of vascular tone and blood pressure by cinacalcet","volume":"323","author":"Fryer","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"2024020318351944200_jbmr1964-bib-0029","first-page":"2548","article-title":"Hemodynamic effects of parathyroid hormone-related peptide-(1-34) in humans","volume":"82","author":"Wolzt","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318351944200_jbmr1964-bib-0030","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med."},{"key":"2024020318351944200_jbmr1964-bib-0031","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jocd.2010.09.001","article-title":"Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis","volume":"14","author":"Schafer","year":"2011","journal-title":"J Clin Densitom."},{"key":"2024020318351944200_jbmr1964-bib-0032","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF03256936","article-title":"Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain - the PROPOSE study","volume":"31","author":"Moricke","year":"2011","journal-title":"Clin Drug Investig."},{"key":"2024020318351944200_jbmr1964-bib-0033","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med."},{"key":"2024020318351944200_jbmr1964-bib-0034","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jc.2008-1763","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop","volume":"94","author":"Bilezikian","year":"2009","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1964","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/10\/2232\/56563414\/jbmr1964.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/10\/2232\/56563414\/jbmr1964.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:49:29Z","timestamp":1710326969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/10\/2232-2243\/7598669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,3]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,5,3]]},"published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1964","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,10,1]]},"published":{"date-parts":[[2013,5,3]]}}}